DOSES STUDIED
Semaglutide dose and dosage, as documented in the trials and label.
The titration ladders, the routes, the half-life — reported third person from the literature, never as a recommendation.
The short version
This page documents the semaglutide dose ranges used in the published trials and the approved label. It is a description of what was studied and what the label states — not a dose for any individual to follow, and not medical advice.
Two things drive every dosing schedule. First, the drug is started low and stepped up slowly ("titration") to limit the nausea that comes with each increase. Second, it lasts about a week, so the injectable form is given once a week and the tablet once a day. The diabetes doses and the weight-management doses differ, and the oral tablet has its own ladder and a strict empty-stomach rule. Every number below is attributed to a trial or the label.
Semaglutide dosage: the subcutaneous titration ladder
The subcutaneous (under-the-skin) schedules are built around slow up-titration. For chronic weight management, the documented schedule steps once weekly from 0.25 mg (weeks 1-4) to 0.5 mg (weeks 5-8), 1.0 mg (weeks 9-12), 1.7 mg (weeks 13-16) and a 2.4 mg maintenance dose. This 2.4 mg maintenance dose is the one studied in STEP 1, where it produced a mean body-weight change of -14.9% at week 68 [1], and in SELECT, where it reduced major cardiovascular events by 20% [3].
For type 2 diabetes, the documented schedule starts at 0.25 mg once weekly for initiation, then 0.5 mg, then a 1.0 mg maintenance dose, with up to 2.0 mg studied in SUSTAIN FORTE — where the 2.0 mg dose lowered HbA1c more than 1.0 mg [12]. The slow climb is the whole point of the ladder: it is what keeps the GI effects tolerable while reaching an effective dose.
Oral semaglutide
Oral semaglutide is the once-daily tablet form, co-formulated with the absorption enhancer SNAC. The documented diabetes ladder is 3 mg daily for 30 days, then 7 mg, then 14 mg daily — the doses established in PIONEER 1, which showed dose-dependent HbA1c and body-weight reductions versus placebo [10]. Higher oral doses (25 mg and 50 mg once daily) have been studied for obesity in the OASIS and PIONEER PLUS programs.
The administration rule is strict because the chemistry demands it. Oral bioavailability is only about 0.4-1% even with SNAC, so the tablet is taken on an empty stomach, 30 minutes before the first food, drink or other oral medication, with no more than about 120 mL of water [20]. Administration errors can substantially reduce the absorbed dose and therefore the effect [20][14] — which is why the fasted routine is part of the dose, not an optional extra.
Semaglutide injection vs the oral route
The semaglutide injection is the once-weekly subcutaneous form; the alternative is the once-daily oral tablet. Both have been studied extensively. The subcutaneous route reaches the bloodstream efficiently and underpins the SUSTAIN, STEP, SELECT and FLOW trials [2][1][3][6]. The oral route trades convenience-of-no-needle for the strict fasted-dosing requirement above and a lower, more variable absorption [20].
The oral form's efficacy in glycemic control and weight, with a cardiovascular profile consistent with the GLP-1 receptor agonist class, is established across the PIONEER program [10]. In short: both routes work, the choice is about format and the absorption trade-off, and both rely on the same week-long half-life to maintain steady drug levels.
Half-life and clearance
Semaglutide's elimination half-life is approximately one week — commonly cited as about 165-168 hours — for both subcutaneous and oral forms, with effectively complete clearance roughly five weeks after the final dose [14]. This long half-life is what allows once-weekly injection and what underlies the pregnancy washout guidance on the Semaglutide effects page.
The duration is conferred by the structure: strong, reversible albumin binding via the C18 fatty di-acid side chain plus DPP-4 resistance from the Aib-8 substitution [14]. Investigational schedules continue to probe the dose ceiling — STEP UP studied a 7.2 mg once-weekly subcutaneous dose for obesity. As always, every figure here is study- or label-attributed and none is a recommendation for any individual.